O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	trial
O	26	28	of
B-intervention	29	45	cyclophosphamide
I-intervention	46	49	and
I-intervention	50	53	the
I-intervention	54	58	oral
I-intervention	59	63	poly
I-intervention	64	65	(
I-intervention	65	68	ADP
I-intervention	68	69	-
I-intervention	69	75	ribose
I-intervention	75	76	)
I-intervention	77	87	polymerase
I-intervention	88	97	inhibitor
I-intervention	98	107	veliparib
O	108	110	in
O	111	119	patients
O	120	124	with
O	125	134	recurrent
O	134	135	,
O	136	144	advanced
O	145	151	triple
O	151	152	-
O	152	160	negative
O	161	167	breast
O	168	174	cancer
O	174	175	.

O	176	186	Background
O	187	189	In
O	190	196	tumors
O	197	205	carrying
O	206	210	BRCA
O	211	220	mutations
O	220	221	,
O	222	225	DNA
O	226	232	damage
O	233	239	caused
O	240	242	by
O	243	251	standard
O	252	261	cytotoxic
O	262	274	chemotherapy
O	275	278	can
O	279	281	be
O	282	293	potentiated
O	294	296	by
O	297	301	poly
O	302	303	[
O	303	306	ADP
O	306	307	-
O	307	313	ribose
O	313	314	]
O	315	325	polymerase
O	326	327	(
O	327	331	PARP
O	331	332	)
O	333	343	inhibitors
O	343	344	,
O	345	352	leading
O	353	355	to
O	356	365	increased
O	366	370	cell
O	371	376	death
O	377	384	through
O	385	394	synthetic
O	395	404	lethality
O	404	405	.

O	406	417	Individuals
O	418	426	carrying
O	427	436	mutations
O	437	439	in
O	440	444	BRCA
O	445	449	have
O	450	452	an
O	453	462	increased
O	463	472	incidence
O	473	475	of
O	476	482	triple
O	483	491	negative
O	492	498	breast
O	499	505	cancer
O	506	507	(
O	507	511	TNBC
O	511	512	)
O	512	513	.

O	514	516	In
O	517	522	order
O	523	525	to
O	526	532	assess
O	533	536	the
O	537	541	role
O	542	544	of
O	545	549	PARP
O	550	560	inhibition
O	561	563	in
O	564	567	the
O	568	577	treatment
O	578	580	of
O	581	585	TNBC
O	585	586	,
O	587	589	we
O	590	599	conducted
O	600	601	a
O	602	612	randomized
O	613	618	phase
O	619	621	II
O	622	627	trial
O	628	630	of
O	631	634	the
O	635	646	combination
O	647	649	of
O	650	659	veliparib
O	659	660	,
O	661	662	a
O	663	668	small
O	669	677	molecule
O	678	682	PARP
O	683	692	inhibitor
O	692	693	,
O	694	698	with
O	699	702	the
O	703	712	cytotoxic
O	713	718	agent
O	719	735	cyclophosphamide
O	736	742	versus
O	743	759	cyclophosphamide
O	760	765	alone
O	766	768	in
O	769	777	patients
O	778	782	with
O	783	793	refractory
O	794	798	TNBC
O	798	799	.

O	800	807	Methods
B-eligibility	808	813	Adult
I-eligibility	814	822	patients
I-eligibility	823	827	with
I-eligibility	828	832	TNBC
O	833	837	were
O	838	848	randomized
O	849	851	to
O	852	859	receive
O	860	864	oral
O	865	881	cyclophosphamide
O	882	884	50
O	885	887	mg
O	888	892	once
O	893	898	daily
O	899	903	with
O	904	906	or
O	907	914	without
O	915	919	oral
O	920	929	veliparib
O	930	932	at
O	933	935	60
O	936	938	mg
O	939	944	daily
O	945	947	in
O	948	950	21
O	950	951	-
O	951	954	day
O	955	961	cycles
O	961	962	.

O	963	971	Patients
O	972	974	on
O	975	978	the
O	979	995	cyclophosphamide
O	996	999	arm
O	1000	1005	could
O	1006	1015	crossover
O	1016	1018	to
O	1019	1022	the
O	1023	1034	combination
O	1035	1038	arm
O	1039	1041	at
O	1042	1049	disease
O	1050	1061	progression
O	1061	1062	.

O	1063	1070	Results
B-total-participants	1071	1076	Forty
I-total-participants	1076	1077	-
I-total-participants	1077	1081	five
O	1082	1090	patients
O	1091	1095	were
O	1096	1104	enrolled
O	1104	1105	;
B-control-participants	1106	1108	18
O	1109	1117	received
B-control	1118	1134	cyclophosphamide
I-control	1135	1140	alone
O	1141	1144	and
B-intervention-participants	1145	1147	21
O	1148	1156	received
O	1157	1160	the
O	1161	1172	combination
O	1173	1175	as
O	1176	1181	their
O	1182	1189	initial
O	1190	1199	treatment
O	1200	1207	regimen
O	1207	1208	.

B-outcome	1209	1220	Lymphopenia
O	1221	1224	was
O	1225	1228	the
O	1229	1233	most
O	1234	1240	common
O	1241	1246	grade
O	1247	1248	3
O	1248	1249	/
O	1249	1250	4
O	1251	1259	toxicity
O	1260	1265	noted
O	1266	1268	in
O	1269	1273	both
O	1274	1278	arms
O	1278	1279	.

B-cv-bin-abs	1280	1283	One
O	1284	1291	patient
O	1292	1294	in
O	1295	1298	the
O	1299	1315	cyclophosphamide
O	1316	1321	alone
O	1322	1325	arm
O	1325	1326	,
O	1327	1330	and
B-iv-bin-abs	1331	1332	2
O	1333	1335	in
O	1336	1339	the
O	1340	1351	combination
O	1352	1355	arm
O	1356	1359	had
B-outcome	1360	1369	objective
I-outcome	1370	1379	responses
O	1379	1380	.

B-outcome	1381	1389	Response
I-outcome	1390	1395	rates
O	1396	1399	and
B-outcome	1400	1406	median
I-outcome	1407	1418	progression
I-outcome	1419	1423	free
I-outcome	1424	1432	survival
O	1433	1436	did
O	1437	1440	not
O	1441	1454	significantly
O	1455	1461	differ
O	1462	1469	between
O	1470	1474	both
O	1475	1484	treatment
O	1485	1489	arms
O	1489	1490	.

O	1491	1501	Conclusion
O	1502	1505	The
O	1506	1514	addition
O	1515	1517	of
O	1518	1527	veliparib
O	1528	1530	to
O	1531	1547	cyclophosphamide
O	1547	1548	,
O	1549	1551	at
O	1552	1555	the
O	1556	1560	dose
O	1561	1564	and
O	1565	1573	schedule
O	1574	1583	evaluated
O	1583	1584	,
O	1585	1588	did
O	1589	1592	not
O	1593	1600	improve
O	1601	1604	the
O	1605	1613	response
O	1614	1618	rate
O	1619	1623	over
O	1624	1640	cyclophosphamide
O	1641	1650	treatment
O	1651	1656	alone
O	1657	1659	in
O	1660	1668	patients
O	1669	1673	with
O	1674	1681	heavily
O	1682	1685	pre
O	1685	1686	-
O	1686	1693	treated
O	1694	1700	triple
O	1700	1701	-
O	1701	1709	negative
O	1710	1716	breast
O	1717	1723	cancer
O	1723	1724	.
